Displaying 61 - 80 of 171
FTC Approves Final Administrative Consent Orders against Companies that Deceptively Marketed Fish Oil Supplements with False Claims They Were Clinically Proven to Treat Liver Disease
Kushly Industries LLC; Analysis of Proposed Consent Order To Aid Public Comment
Quickwork LLC and Eric A. Nepute
In April 2021, the FTC charged St. Louis-based chiropractor Eric Anthony Nepute and his company Quickwork LLC with violating the COVID-19 Consumer Protection Act and the Federal Trade Commission Act, by deceptively marketing products containing vitamin D and zinc as scientifically proven to treat or prevent COVID-19. This is the first such case in which the agency has sought civil penalties.
The FTC Directed 30 More Marketers to Stop Making Unsupported Claims That Their Products and Therapies Can Effectively Prevent or Treat COVID-19
Opening Statement Of Acting Chairwoman Rebecca Kelly Slaughter before the United States House Committee on Energy and Commerce Subcommittee on Consumer Protection and Commerce: The Urgent Need To Fix Section 13(B) Of The FTC Act
FTC Testifies before Congress on its Work to Curb COVID-19 Scams and Warn Consumers about Pandemic-related Frauds, Cons, and Swindles
Prepared Statement of the Federal Trade Commission: The Urgent Need to Fix Section 13(b) of the FTC Act
Prepared Statement of the Federal Trade Commission: Curbing COVID Cons: Warning Consumers about Pandemic Frauds, Scams, and Swindles
Prepared Statement of Acting Chairwoman Rebecca Kelly Slaughter: Strengthening the Federal Trade Commission's Authority to Protect Consumers
Prepared Statement of Commissioner Christine S. Wilson: Strengthening the Federal Trade Commission's Authority to Protect Consumers
Prepared Statement of Commissioner Noah Joshua Phillips: Strengthening the Federal Trade Commission's Authority to Protect Consumers
Prepared Statement of Commissioner Rohit Chopra: Strengthening the Federal Trade Commission's Authority to Protect Consumers
Prepared Statement of the Federal Trade Commission: Strengthening the Federal Trade Commission's Authority to Protect Consumers
Protecting Consumers During the COVID-19 Pandemic: A Year in Review
One Year into COVID-19 Pandemic, New FTC Staff Report Highlights Agency’s Ongoing Efforts to Protect Consumers
BASF SE and DIEM Labs; Analysis of Proposed Consent Orders To Aid Public Comment
FTC Approves Final Administrative Consent Orders against Sellers of Deceptively Marketed CBD Products
CBD Meds, Inc., In the Matter of
In December 2020, the FTC announced its first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The Commission took action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others. A summary of the proposed orders settling the agency’s respective complaint can be found on the FTC’s website as a link to each case. The FTC announced final approval of all six orders in March 2021.
CBD Meds, Inc. The proposed administrative order prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. More broadly, it requires them to have competent and reliable scientific evidence when making any other health-related product claims. It requires the respondents to notify consumers of the Commission’s order.
Epichouse LLC, (First Class Herbalist CBD), In the Matter of
In December 2020, the FTC announced its first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The Commission took action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others. A summary of the proposed orders settling the agency’s respective complaints can be found on the FTC’s website as a link to each case. The FTC announced final approval of all six orders in March 2021.
Epichouse LLC. The proposed administrative order prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It requires them to have competent and reliable scientific evidence when making any other health-related product claims. It requires the respondents to pay $30,000 to the FTC and notify consumers of the Commission’s order.
Displaying 61 - 80 of 171